SynthesisScience China. Life sciences2026
Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.
Synthesis in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advancements in diagnosis and treatments of acute leukemia.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Biomarker-empowered precision navigation of CAR-T cell therapy.Molecular cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor-T (CAR-T) cell therapy has made considerable advancements in the treatment of malignant tumors; however, its clinical application continues to face challenges such as low response rates and relapse, which are critical issues requiring urgent resolution. The insufficient functionality of CAR-T cells remains a core factor affecting their clinical efficacy. This article provides a systematic review of various strategies to enhance CAR-T cell functionality, including structural modification and gene editing of chimeric antigen receptor CAR molecules, optimization of manufacturing processes, enhancement of CAR-T cells to counteract the inhibitory tumor immune microenvironment, and combination therapies with other drugs. In terms of optimizing CAR molecules, particularly the development of dual-target CARs, this approach not only effectively prevents antigen escape but also significantly enhances the activation, proliferation, and anti-tumor efficacy of CAR-T cells. Gene editing technology offers new opportunities to improve the persistence, proliferative capacity, and anti-tumor activity of CAR-T cells, thereby enhancing their function and reducing disease relapse. Furthermore, epigenetic regulation augments the adaptability of CAR-T cells, strengthening their anti-tumor effects. Simultaneously, combining CAR-T cell therapy with other immunotherapies provides fresh perspectives for improving overall treatment efficacy. However, challenges remain in areas such as the precision of gene editing, reversibility of epigenetic regulation, and optimization of CAR structures. Future research should focus on refining these strategies and exploring their synergistic applications to maximize the therapeutic potential of CAR-T cell therapy. With ongoing technological advancements, CAR-T cell therapy is poised to achieve groundbreaking applications in a broader range of malignant tumor treatments, offering new hope to patients.
Indexed as
Identifiers
41627668What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.